Captrust Financial Advisors Myovant Sciences Ltd. Transaction History

Captrust Financial Advisors

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	SELL	$24.03 - $27.02 $1.06 Million - $1.19 Million	-44,000 Reduced 62.74%	26,133 $704,000
Q3 2022 Nov 16, 2022	SELL	$11.6 - $20.44 $1,160 - $2,044	-100 Reduced 0.14%	70,133 $1.26 Million
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $1,138 - $1,639	100 Added 0.14%	70,233 $936,000
Q3 2021 Nov 16, 2021	BUY	$18.94 - $26.99 $476,019 - $678,339	25,133 Added 55.85%	70,133 $1.57 Million
Q2 2021 Aug 16, 2021	BUY	$17.07 - $24.56 $17,070 - $24,560	1,000 Added 2.27%	45,000 $1.03 Million
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $24,756 - $30,467	1,210 Added 2.83%	44,000 $906,000
Q4 2020 Feb 16, 2021	BUY	$13.8 - $27.62 $37,950 - $75,955	2,750 Added 6.87%	42,790 $1.18 Million
Q3 2020 Nov 17, 2020	BUY	$14.05 - $22.6 $224,800 - $361,600	16,000 Added 66.56%	40,040 $560,000
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $29,653 - $84,193	4,040 Added 20.2%	24,040 $484,000
Q4 2019 Feb 14, 2020	BUY	$4.2 - $19.21 $84,000 - $384,200	20,000 New	20,000 $295,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.